XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Additions and Returns of Product Rights - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 24 Months Ended
Nov. 30, 2018
Nov. 30, 2016
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2021
Jul. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]                
Payment to acquire business upon closing       $ 0 $ 5,000,000      
Clinigen                
Business Acquisition [Line Items]                
Revenue         8,800,000      
Direct expenses         5,500,000      
Discontinued operations income       2,300,000 $ 3,300,000      
Inventory               $ 500,000
Clinigen | Scenario, Forecast                
Business Acquisition [Line Items]                
Financial consideration received in exchange for product license rights           $ 5,000,000    
Nordic                
Business Acquisition [Line Items]                
Revenue     $ 500,000          
Vibativ                
Business Acquisition [Line Items]                
Payment to acquire business upon closing $ 20,000,000.0     20,000,000        
Cash payment during 2019 $ 5,000,000.0     5,000,000        
Percentage of tiered royalty payments (up to) 20.00%              
Additional liability     8,105,578 8,105,578       $ 8,633,589
Net intangible assets     11,750,000 11,750,000        
Vibativ | Other current liabilities                
Business Acquisition [Line Items]                
Additional liability     2,800,000 2,800,000        
Vibativ | Other long-term liabilities                
Business Acquisition [Line Items]                
Additional liability     5,300,000 5,300,000        
Methotrexate                
Business Acquisition [Line Items]                
Payment to acquire business upon closing   $ 100,000            
Additional liability             $ 1,000,000.0  
Liability recorded   $ 900,000            
Vested common stock, value       900,000        
Net intangible assets     $ 1,900,000 $ 1,900,000        
Methotrexate | Restricted Stock                
Business Acquisition [Line Items]                
Unvested restricted shares (in shares)   180,000